NEXI
Neximmune Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
neximmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary aim™ technology. this nanotechnology platform, originally developed at johns hopkins university, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted t cell response against a disease. central to the aim technology are artificial antigen presenting cells (aapc) that present antigens to t cells eliciting a highly targeted therapy driven by the patient’s immune system. these aapc can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.
Market Cap: 90.5 Million
Primary Exchange: NASDAQ
Website: neximmune.com
Shares Outstanding: 13.9 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 968 trading days
From: 2021-02-26 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|